Clinical trials: Osteoporosis Postmenopausal
Menopause, Osteopenia
Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women
The present research program is proposed deepening some pharmacological effects of the genistein therapy in order to individualize alternative treatments to the conventional hormonal replacement therapy useful to reduce the…
- Trial name
- NCT00355953
- Testing
- Genistein
- Volunteers
- 400 people
- Sponsor
- University of Messina
Postmenopausal Osteoporosis
The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)
In 2006, Weinberg proposed a hypothesis that iron accumulation was a risk factor for osteoporosis. Osteoporosis is a common complication in various diseases, such as hemochromatosis, African hemosiderosis, thalassemia, and sickle…
- Trial name
- PMOP (NCT02854722)
- Testing
- Deferasirox and calcium-vitamin D3, Calcium-vitamin D3
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Soochow University
Osteoporosis, Menopause
MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis
Osteoporosis is a systemic skeletal disorder affecting approximately 10% of individuals over 50 years of age. It is characterised by an increased risk of fragility fractures, which constitute a major source of morbidity…
- Trial name
- ROMIRNA (NCT07616401)
- Testing
- miRNA typing
- Where
- 2 sites in Italy
- Volunteers
- 42 people
- Sponsor
- Istituto Auxologico Italiano
Menopause, Osteoporosis
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal…
- Trial name
- NCT00808132
- Testing
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg
- Where
- 178 sites in United States, Argentina and 10 more
- Volunteers
- 1,886 people
- Sponsor
- Pfizer
Osteoporosis, Postmenopausal
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts
- Trial name
- NCT04974723
- Testing
- Abaloparatide, Teriparatide
- Where
- United States
- Volunteers
- 22,054 people
- Sponsor
- Radius Health, Inc.
Osteoporosis
The Forteo Alendronate Comparator Trial
The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
- Trial name
- FACT (NCT02416271)
- Testing
- Teriparatide, Alendronate, Calcium
- Where
- 20 sites in United States, Brazil and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice
The vitamin D deficiency (25OHD) is very common and affects about 80% of the population of French osteoporotic women over 50 years [5]. It contributes significantly to bone fragility and consequently the risk of fracture.
- Trial name
- VITAD (NCT02518763)
- Testing
- Vitamin D3, 100 000 IU weekly, 4 times, 25 OH vitamin D serum concentration measurements
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
Osteoporosis, Postmenopausal
Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women
To evaluate the effect of estrogen treatment on adipocytic and osteoblastic parameters by histomorphometrically measuring adipocyte volume (AV/TV) and adipocyte numbers in goldner's stained iliac crest bone biopsy specimens…
- Trial name
- NCT00443716
- Testing
- estrogen
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Osteopenia
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.
- Trial name
- NCT00132808
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
Effect of Postural Correction Exercises on Pelvic Floor Dysfunction in Postmenopausal Osteoporotic Women
This study aimed to investigate the effect of postural correction exercises on pelvic floor dysfunction in postmenopausal osteoporotic women
- Trial name
- NCT07806968
- Testing
- Estrogen replacement therapy, General advice, Postural correction exercise program
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Breast Cancer
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
The purpose of this study is to determine whether zoledronic acid given intravenously every 6 months can prevent reduction in bone mineral density in women with early stage breast cancer receiving adjuvant therapy with the…
- Trial name
- NCT00376740
- Testing
- zoledronic acid
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Soroka University Medical Center
Cardiovascular Diseases, Osteoporosis
A Study on the Impact of Calcium on Woman's Vascular Health
The overarching aim of this randomized clinical trial is to estimate the effect of dietary intake of calcium as compared to supplemental calcium on the vascular system and markers of vascular and bone health in postmenopausal…
- Trial name
- NCT01731340
- Testing
- Calcium Citrate, Low Dietary Calcium, High Dietary Calcium
- Where
- Canada
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Osteoporosis, Postmenopausal
Comparative Efficacy, Safety, PK, and Immunogenicity Study
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women…
- Trial name
- NCT05853354
- Testing
- Denosumab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 392 people
- Sponsor
- Luye Pharma Group Ltd.
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Osteoporosis, Osteopenia, Hypercholesterolemia
Effect of Pitavastatin on Bone
This clinical trial investigates the effects of pitavastatin on bone health in postmenopausal women with osteopenia or osteoporosis and hypercholesterolemia.
- Conditions
- Osteoporosis, Osteopenia, Hypercholesterolemia, Menopausal Osteoporosis
- Trial name
- NCT06359353
- Testing
- Pitavastatin
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Seoul National University Bundang Hospital
Age-Related Osteoporosis
Training in a Local Community Aimed Upon Musculoskeletal Health Promotion for Postmenopausal Women
To minimize fracture risk, diverse and varied training of high intensity (multimodal training) is recommended to increase bone strength.
- Trial name
- NCT05164679
- Testing
- multimodal training (MMT)
- Where
- Denmark
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Osteoporosis, Postmenopausal
OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
To determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide; The primary objective of the study is to compare the teriparatide…
- Trial name
- NCT00130403
- Testing
- risedronate sodium
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 290 people
- Sponsor
- Sanofi
Postmenopausal Osteoporosis
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis.
- Trial name
- NCT00529373
- Testing
- Odanacatib, Vitamin D3, Calcium carbonate
- Volunteers
- 16,071 people
- Sponsor
- Merck Sharp & Dohme LLC
Postmenopausal Osteoporosis
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.
- Trial name
- NCT00079924
- Testing
- teriparatide, aldrenodate, raloxifene
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.
- Trial name
- NCT04664959
- Testing
- SB16 (Proposed Denosumab Biosimilar), Prolia® (Denosumab)
- Where
- 5 sites in Poland
- Volunteers
- 457 people
- Sponsor
- Samsung Bioepis Co., Ltd.